Metyos, a Paris, France-based medtech startup, raised €2.3M in Pre-Seed funding.
The round was led by Cenitz with participation from KIMA Ventures, Advans Lab, Bpifrance, and others.
The company intends to use the funds to progress the technology through clinical trials ahead of regulatory approval.
Founded by CEO Alexandre Boulanger and CTO Olga Chashchina, Metyos is a medtech startup advancing treatments for chronic kidney disease (CKD) patients worldwide with its biowearable sensor and disease management platform. Its technology offers continuous health monitoring, empowering patients and healthcare professionals to make informed, real-time decisions.
The company is currently seeking participants for clinical trials to further evaluate and refine its biowearable technology.
Commenting on the news, Alexandre Boulanger said: “Our mission at Metyos is to move healthcare away from reactive care towards proactive disease management. A healthcare future where millions of CKD patients are empowered to take control of their health, and where they can access life-saving early detection and personalised interventions. This funding, and the support and belief of the brilliant investors it brings with it, will help make this future a reality and help change the lives of so many patients and medical professionals worldwide.”
FinSMEs
26/03/2024